<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0"><channel><title>NIDDK Research Materials</title><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing</link><description>A selection of the biological materials such as antibodies, cell lines, and mouse models, experimental therapeutic compounds, and devices developed by NIDDK scientists that are made available to the global research community for further research and development.</description><language>en</language><item><guid isPermaLink="false">{06B27936-B75F-4572-8D8A-B176E1F8543D}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/inverse-agonists-neutral-antagonists-tsh-receptor</link><title>Inverse agonists &amp; neutral antagonists for the tsh receptor (U.S. Patent Application Number WO 2011127388 A2)</title><description>&lt;p&gt;&lt;p&gt;TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Fri, 01 Mar 2024 12:31:32 -0500</pubDate></item><item><guid isPermaLink="false">{65716DD8-78DF-4924-87C2-9A23182368C1}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/thyclotide-peptide-conjugates-with-cell-permeability-and-inhibitory-activity</link><title>Thyclotide Peptide Conjugates with Cell Permeability &amp; Inhibitory Activity</title><description>&lt;p&gt;Thyclotides are oligomeric molecules with chiral tetrahydrofuran (THF) diamine units consisting of either R,R orS,S stereochemistry. Thyclotide sequences with R,R stereochemistry bind to complementary DNA and RNAsequences with strong affinity and sequence specificity, while thyclotides with S,S stereochemistry have a helicalhandedness that does not allow binding to DNA or RNA. Thyclotides are cell permeable and can be used tosuppress microRNA activity in cells. Peptides are oligomeric molecules consisting of amino acids found inproteins as well as other non-natural amino acids. Peptides are often developed as inhibitors of enzymes andprotein-protein interactions, yet peptides typically are poor drugs as they do not penetrate cell membranestherefore have low bioactivity. NIDDK investigators have discovered that thyclotides can be covalentlyconjugated to peptides that are enzyme inhibitors to enhance the cell permeability of the peptide. Usingthyclotide to enhance peptide cell penetration is a novel way to help peptides gain entry into cells to improvetheir bioavailability. Using thyclotides+peptide conjugates may greatly expand the range of therapeuticapplications of peptide inhibitors.&lt;/p&gt;</description><pubDate>Fri, 09 Feb 2024 14:51:07 -0500</pubDate></item><item><guid isPermaLink="false">{0F881633-C8E4-44E8-A118-C900EFD05A9E}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/sidechain-functionalized-s-acylbenzamides-with-anti-hiv-activity</link><title>Sidechain Functionalized S-acylbenzamides With Anti-HIV Activity</title><description>&lt;p&gt;HIV infection remains a major medical problem, with approximately 38 million people worldwide livingwith HIV. Nipamovir and SAMT-247 are simple and inexpensive small molecules that inactivate HIVvirus by interference with final maturation steps of the virus. This mechanism provides a high barrierfor HIV to develop resistance. In fact, lab experiments designed to encourage HIV to developresistance to Nipamovir and SAMT-247 have all failed. In animal tests, Nipamovir and SAMT-247 donot display toxic side effects. SAMT-247 is an effective microbicide that can be used to block HIVinfection in animal models. Both Nipamovir and SAMT-247 are rapidly metabolized in blood wherethe sulfur of molecule is methylated, resulting in loss of antiviral activity. By attaching specificsidechains to the S-acylbenzamide scaffold of Nipamovir and SAMT-247, NIDDK investigators havedeveloped new molecules that have improved anti-HIV activity and also are resistant to metabolism inblood.&lt;/p&gt;</description><pubDate>Fri, 09 Feb 2024 13:59:38 -0500</pubDate></item><item><guid isPermaLink="false">{15AC7A6B-3C8A-4F8D-8054-5FFDDDCA2C07}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/detecting-thalassemia</link><title>Simple, rapid &amp; reliable method for detecting thalassemia (U.S. Patent Number 5,281,519)</title><description>&lt;p&gt;A simple, rapid and reliable method for diagnosis of thalassemia is described. The method comprises amplification of the cDNA by polymerase chain reaction and determining the ratio between α and β hemoglobin chain mRNAs.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:37:45 -0500</pubDate></item><item><guid isPermaLink="false">{C6A1EE47-1B11-4431-B25F-F7D246753C16}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/diagnosing-alpha-thalassemia</link><title>Rapid method for diagnosing the various forms of alpha-thalassemia (U.S. Patent Number 6,322,981)</title><description>&lt;p&gt;The present invention relates to the simultaneous and specific identification of the variant forms of α-thalassemia. This invention utilizes simple and readily available equipment to rapidly identify, diagnose and differentiate the different forms of α-thalassemia. Specifically, the present invention relates to a simple and rapid non-radioisotopic technique for the diagnosis and differentiation of the common forms of α-thalassemia has been developed. This approach works on any biological tissue including blood, wherein the assay works equally well with fresh blood and dried blood samples stored on filter paper.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:36:45 -0500</pubDate></item><item><guid isPermaLink="false">{79E9EFFA-536B-4F03-A667-8DFE5059EEF0}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/ormdl2-ko-mouse</link><title>Ormdl2 KO Mouse</title><description>&lt;p&gt;&lt;strong&gt;Also known as: &lt;/strong&gt;C57BL/6-&lt;em&gt;Ormdl2&lt;/em&gt;&lt;sup&gt;em1Rlp&lt;/sup&gt;/J&lt;/p&gt;&lt;p&gt;ORMDL proteins (ORMDL1, 2 and 3) are a family of small transmembrane endoplasmic reticulum proteins involved in feedback inhibition of the de novo synthesis pathway of sphingolipids by inhibiting serine palmitoyltransferase in response to elevated ceramide levels.&lt;/p&gt;&lt;p&gt;&lt;em&gt;Ormdl2 &lt;/em&gt;KO mice carry a CRISPR/Cas9 generated 26 bp deletion in exon 2 resulting in premature termination of sequence. This strain useful when studying sphingolipid metabolism and myelination defects. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/31880535"&gt;Learn more on  PubMed: 31880535&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Mice can be obtained from Jackson Labs.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:35:44 -0500</pubDate></item><item><guid isPermaLink="false">{FA21728B-A44C-44A9-9390-1BC23C6B7062}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/ormdl1-ko-mouse</link><title>OrmdI1 KO Mouse</title><description>&lt;p&gt;&lt;strong&gt;Also known as:&lt;/strong&gt; C57BL/6-&lt;em&gt;Ormdl1&lt;/em&gt;&lt;sup&gt;em1Rlp&lt;/sup&gt;/J&lt;/p&gt;&lt;p&gt;ORMDL proteins (ORMDL1, 2 and 3) are a family of small transmembrane endoplasmic reticulum proteins involved in feedback inhibition of the de novo synthesis pathway of sphingolipids by inhibiting serine palmitoyltransferase in response to elevated ceramide levels.&lt;/p&gt;&lt;p&gt;&lt;em&gt;Ormdl1 KO&lt;/em&gt; mice carry a CRISPR/Cas9 generated 13 bp deletion in exon 2 resulting in premature termination of sequence. This strain useful when studying sphingolipid metabolism and myelination defects. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/31880535"&gt;Learn more on PubMed: 31880535&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Mice can be obtained from Jackson Labs.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:34:46 -0500</pubDate></item><item><guid isPermaLink="false">{0B6EE95E-5FF6-4B2E-B3D3-504A3B342252}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/inducible-spt-model</link><title>Inducible SPT Mouse</title><description>&lt;p&gt;&lt;strong&gt;Also known as:&lt;/strong&gt;  Floxed stop fusion-serine palmitoyl transferase mouse, Stop-fSPT mouse, B6J.FVB-&lt;em&gt;Gt(ROSA)26Sor&lt;/em&gt;&lt;sup&gt;&lt;em&gt;tm3(CAG-SPTLC2/SPTSSA/SPTLC1,-EGFP)1Rlp&lt;/em&gt;&lt;/sup&gt;/Mmucd&lt;/p&gt;&lt;p&gt;The mice carry a transgene that is a single-chain version of serine palmitoyltransferase with its three core (human) subunit cDNAs, &lt;em&gt;SPTLC2&lt;/em&gt;,&lt;em&gt; SPTSSA&lt;/em&gt;, and&lt;em&gt; SPTLC1 &lt;/em&gt;fused into a single reading frame linked T2A-separated EGFP under control of a promoter that is activated by Cre recombinase expression (Stop-fSPT). The transgene was inserted into the Gt(ROSA)26Sor locus.&lt;/p&gt;&lt;p&gt;When bred to mice that express tissue-specific Cre recombinase, resulting offspring will overexpression the first enzyme of the sphingolipid metabolism pathway resulting in elevation of sphingolipid synthesis. This strain useful when studying sphingolipid metabolism. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/31880535"&gt;Learn more on PubMed: 31880535&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Mice can be obtained from MMRRC.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:33:22 -0500</pubDate></item><item><guid isPermaLink="false">{FE6F8A23-2795-43CB-BCB1-B516E95D888B}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/heterocyclic-p2y14-antagonists</link><title>Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions</title><description>&lt;p&gt;The technology discloses composition of compounds that are highly selective P2Y14 receptor antagonists, with moderate affinity with insignificant antagonism of other P2Y receptors. These compounds might provide a treatment for patients for various disease conditions, including lung inflammation, kidney inflammation, asthma, diabetes, obesity, and neuropathic pain of diverse states. In vivo data using mouse lines with the receptor knocked out in specific tissues showed that P2Y14 receptor antagonists act on adipocytes to improve conditions of metabolic disorders. Though there are no P2Y14 receptor modulators in clinical use currently, selective P2Y14 receptor antagonists are sought as potential therapeutic treatments for asthma, chronic pain, inflammation and possibly diabetes and neurodegeneration.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:32:51 -0500</pubDate></item><item><guid isPermaLink="false">{021E2D0A-9D36-49B0-9ABE-D543539B4823}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/floxed-ormdl3-mouse</link><title>Floxed Ormdl3 Mouse</title><description>&lt;p&gt;&lt;strong&gt;Also known as:&lt;/strong&gt; B6.Cg-&lt;em&gt;Ormdl3&lt;/em&gt;&lt;sup&gt;tm1.1Rlp&lt;/sup&gt;/J&lt;/p&gt;&lt;p&gt;ORMDL proteins (ORMDL1, 2 and 3) are a family of small transmembrane endoplasmic reticulum proteins involved in feedback inhibition of the de novo synthesis pathway of sphingolipids by inhibiting serine palmitoyltransferase in response to elevated ceramide levels.&lt;/p&gt;&lt;p&gt;Mice that are homozygous for this &lt;em&gt;Ormdl3 floxed&lt;/em&gt; allele are viable and fertile. When bred to mice that express tissue-specific Cre recombinase, resulting offspring will have exons 2-3 and part of exon 4 deleted in the Cre-expressing tissues. This strain useful when studying sphingolipid metabolism and myelination defects. &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/31880535"&gt;Learn more on  PubMed: 31880535&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Mice can be obtained from Jackson Labs.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:31:00 -0500</pubDate></item><item><guid isPermaLink="false">{08B387DD-902B-4E00-BE95-546083CE1F38}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/nucleic-acid-sequence-variations-mu-transposase</link><title>Detection of nucleic acid sequence variations using phase Mu transposase (U.S. Patent Number 7,316,903)</title><description>&lt;p&gt;The present invention relates, e.g., to a method of detecting a mismatch in a double stranded nucleic acid target, comprising (a) contacting the target with (i) a Mu-end nucleic acid, and (ii) a phage Mu transposase, under conditions effective for the Mu-end nucleic acid to transpose into the target at about the site of a mismatch, if the target comprises a mismatch, and (b) detecting transposition of the Mu-end DNA into the target, wherein transposition of the Mu-end nucleic acid into the target at a predominant site indicates the presence of a mismatch at that site.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:27:08 -0500</pubDate></item><item><guid isPermaLink="false">{0C41164C-2901-4AB4-920A-F808100BA4EE}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/a3-adenosine-receptor-positive-allosteric-modulators</link><title>A3 Adenosine Receptor Positive Allosteric Modulators</title><description>&lt;p&gt;Selective A3AR agonists are sought as potential agents for treating inflammatory diseases, chronic pain, cancer and non-alcoholic steatohepatitis (NASH). NIDDK investigators have invented new chemical composition as positive allosteric modulators (PAMs) of the A3AR. These chemical compounds contain sterically constrained, bridged modifications and cycloalkyl rings of various sizes, as well as modifications of the 4-arylamino group. The compounds have added three-dimensionality to otherwise flat molecules, which helps distinguish their positive (desired) and negative (undesired) pharmacological effects on the action of A3AR agonists. Unlike agonists that have side effects, PAM action can be event- and site-specific because adenosine is endogenously elevated in response to localized distress signals within the body.&lt;/p&gt;</description><pubDate>Mon, 29 Jan 2024 18:26:21 -0500</pubDate></item><item><guid isPermaLink="false">{C9D9B2B6-43F4-406F-A562-4687E8E76DC2}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/a3-adenosine-receptor-allosteric-modulators</link><title>A3 Adenosine receptor allosteric modulators (U.S. Patent Number 20090054476 A1)</title><description>&lt;p&gt;&lt;p&gt;The present invention relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering to a subject an amount of an A3RM, the amount being effective to modulate A3AR activity. The A3RM according to the invention are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. The invention also provides some of such novel 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Tue, 07 Nov 2023 12:32:26 -0500</pubDate></item><item><guid isPermaLink="false">{57F92826-B814-4A6F-9E1F-759E8EAF0337}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/therapeutic-polypeptides</link><title>Therapeutic Polypeptides &amp; Their Use (U.S. Patent Application Number 61/890,585)</title><description>&lt;p&gt;&lt;p&gt;NIDDK investigators have developed a synthetic polypeptide with beneficial effects and prospective treatment of chronic kidney disease (CKD). End stage renal disease (ESRD) is a major health and economic burden and requires transplantation or dialysis to avoid imminent death. ESRD is the final stage of CKD, which progresses over the course of decades. The major causes of CKD are diabetes and hypertension, and treatments for diabetes and hypertension are only partially effective to slow the progression of CKD. Only one class of drugs Angiotensin Converting Enzyme inhibitors and/or Angiotensin Receptor Blockers (ACEi/ARB) is effective for slowing CKD progression, but many CKD patients, especially African Americans, are resistant to ACEi/ARB therapy. Several anti-oxidant/anti-fibrotic agents (including bardoxolone and pirfenidone) have not shown efficacy in recent clinical trials. Therefore, novel therapeutic approaches are needed for this large unmet medical need. The investigators previously demonstrated in a mouse preclinical model that CD36 is important for developing CKD, where deletion of the CD36 gene prevented most of the progression of CKD. Subsequently, they tested whether peptides designed to inhibit CD36 action could also prevent the progression of CKD.&lt;/p&gt;&lt;p&gt;CKD is highly prevalent in the US, affecting more than 20 million people. African Americans have a higher risk than Caucasians.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:47:57 -0400</pubDate></item><item><guid isPermaLink="false">{2DA2D0B2-821E-48E3-8264-5C34897C8F74}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/synthesis-purification-hepatitis-c-virus-particles</link><title>Synthesis &amp; purification of hepatitis C virus-like particles (U.S. Patent Number 6,387,662)</title><description>&lt;p&gt;&lt;p&gt;Production of enveloped RNA virus-like particles intracellularly in vitro in insect cells using a recombinant baculovirus vector containing a cDNA coding for viral structural proteins is disclosed. In vitro production and purification of hepatitis C virus (HCV)-like particles containing HCV core protein, E1 protein and E2 protein is disclosed. Production of antibodies in vivo to the purified HCV-like particles is disclosed.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:47:36 -0400</pubDate></item><item><guid isPermaLink="false">{7935E453-1C10-47EE-B711-A887C89B1EAC}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/specialized-tissue-collection-device-preservation-transportation-needle-biopsies</link><title>A Specialized Tissue Collection Device for the Preservation &amp; Transportation of Needle Biopsies (U.S. Patent Number 16/606,555)</title><description>&lt;p&gt;The ability to hold and transport tissue, especially needle biopsies in a pre-defined and controlled environment is critical for the preservation of biopsy samples in downstream analytic applications. Currently, tissue specimens are placed in open containers with variable, poorly controlled solutions applied to them, often in less than sterile conditions.  Evaluation of the tissue by examination through a stereoscope or similar approaches to determine adequacy is limited and requires manipulation of the tissue that can further damage the tissue. The entire process lacks standardization, which is in stark contrast to the handling of blood, that is collected and transported in well-defined containers that have individualized pre-analytic preservatives and downstream protocols.&lt;/p&gt;&lt;p&gt;Researchers at National Institutes of Health (NIH) have developed a tissue collection and storage container that allows for the direct deposition of tissue into the container while stabilizing the sample for transport in a specific solution and/or gas. This new device will primarily be used for needle biopsies to collect tissue samples and maintain their integrity for subsequent analysis. Additional features of the tissue storage container will include materials to physically stabilize and allow for direct examination of the sample by microscopy.&lt;/p&gt;&lt;p&gt;This system is available for co-development or licensing to interested companies.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:47:12 -0400</pubDate></item><item><guid isPermaLink="false">{3D17688B-F914-49F8-961D-3F8E04A402CE}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/polycystic-kidney-disease-gene-protein</link><title>Polycystic kidney disease gene &amp; protein (U.S. Patent Number 6,071,717)</title><description>&lt;p&gt;The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells transformed with the vectors, and methods for producing PKD1 protein or fragments thereof. In another aspect, the invention involves isolated oligonucleotides that hybridize only to the authentic expressed PKD1 gene, and not to PKD1 homologues. In yet another aspect, the invention involves isolated mutant PKD1 genes, and their cDNA cognates. Further provided are isolated oligonucleotides that discriminate between normal and mutant versions of the PKD1 gene. Methods and compositions for treating APKD or disease conditions having the characteristics of APKD are also provided.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:46:39 -0400</pubDate></item><item><guid isPermaLink="false">{393CF67C-D91D-4285-8471-DDA8D12FDE2B}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/pkd-mutations-evaluation</link><title>Pkd mutations &amp; evaluation of same (U.S. Patent Number 10,760,128)</title><description>&lt;p&gt;The present invention relates to methods of detecting novel mutations in a PKD1 and/or PKD2 gene that have been determined to be associated with autosomal dominant polycystic kidney disease (ADPKD) in order to detect or predict the occurrence of ADPKD in an individual.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:46:15 -0400</pubDate></item><item><guid isPermaLink="false">{5260C7E8-C998-4FB9-B816-55DDFB6B8EF8}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/personalized-body-weight-management-system</link><title>Personalized Body Weight Management System Using Monitoring Devices &amp; Mathematical Models of Metabolism</title><description>&lt;p&gt;Attempts to manage body weight are often unsuccessful or only temporary. This is, in part, due to antiquated dieting methods that attempt to address calorie consumption while ignoring metabolic and physical changes. Personalized and more comprehensive methods to track and manage body weight may be more effective.  To that end, scientists at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) developed and launched the &lt;a href="/health-information/weight-management/body-weight-planner"&gt;Body Weight Planner&lt;/a&gt; that uses validated mathematical models of human metabolism to set weight management goals and predict individual body weight outcomes in the context of changing metabolic needs and calorie consumption.&lt;/p&gt;&lt;p&gt;More recently, developers at NIDDK have created a prototype personalized body weight management system prototype that builds on the science behind Body Weight Planner with the addition of patented tracking and feedback technology.  This new system is targeted for use by professionals and is designed to be integrated into a comprehensive healthcare or wellness program.  Improvements enable users to more accurately plan, track, and update personalized weight management interventions by accounting for changes in human appetite, metabolism, and calorie expenditure over time. There are opportunities for the prototype to be combined with other devices to provide data input through wearables and at-home measurements. This system provides meaningful feedback through enhanced functionality and features to meet weight management goals.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:45:37 -0400</pubDate></item><item><guid isPermaLink="false">{D9BCE181-75CC-490D-B684-644B6D9400D9}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/mini-mu-plasmid-rapid-dna-sequencing</link><title>Mini Mu containing plasmid &amp; a method for rapid DNA sequencing (U.S. Patent Number 4,716,105)</title><description>&lt;p&gt;&lt;p&gt;The present invention discloses a rapid method of sequencing a relatively large segment of deoxyribonucleic acid. The method in part comprises high frequency insertion of a suitable transposon into a segment of DNA of interest. Preferable use of Mu transposons is described. A plasmid having mini-Mu transposons has been prepared and disclosed.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:44:13 -0400</pubDate></item><item><guid isPermaLink="false">{EF8906DE-A2E2-494B-909C-0AC7452AD964}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/methanocarba-adenosine-derivatives</link><title>(N)-Methanocarba Adenosine Derivatives &amp; Their Dendrimer Conjugates as A3 Receptor Agonists (U.S. Patent Application Number 61/313,961)</title><description>&lt;p&gt;&lt;p&gt;Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. Also disclosed are conjugates comprising a dendrimer and one or more ligands, which are functionalized congeners of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily. Such conjugates are have the potential of being used as dual agonists, dual antagonists, or agonist/antagonist combinations.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:43:54 -0400</pubDate></item><item><guid isPermaLink="false">{5C4B4D36-331C-4873-BC40-1B22E94689E0}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/men1-gene-endocrine-neoplasia-type-1</link><title>MEN1, the gene associated with multiple endocrine neoplasia type 1, menin polypeptides &amp; uses thereof (U.S. Patent Number 7,358,347)</title><description>&lt;p&gt;&lt;p&gt;The invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated mutations in the corresponding gene have been identified in individuals suffering from multiple endocrine neoplasia type 1. The identification of this marker for multiple endocrine neoplasia type 1 has diagnostic uses as well as for gene therapy.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:43:22 -0400</pubDate></item><item><guid isPermaLink="false">{332A6931-01BB-4471-83D9-DBC00A599F33}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/m3-muscarinic-receptor-ko-mouse</link><title>M3 Muscarinic Receptor Knockout mice are hypophagic, lean, &amp; have improved glucose tolerance &amp; insulin sensitivity</title><description>&lt;p&gt;&lt;p&gt;M3 Muscarinic Receptor Knockout mice are hypophagic, lean, and have improved glucose tolerance and insulin sensitivity.&lt;/p&gt;&lt;p&gt;The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M3 muscarinic ACh receptors are present in the central nervous system and the periphery.&lt;/p&gt;&lt;p&gt;M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype. This results from a combination of reduced caloric intake and increased energy expenditure. They eat less food than wild-type mice, possibly because a central cholinergic pathway that stimulates food intake is disrupted. They also expend more energy. Because of their lean phenotype, M3R knockout mice have improved glucose tolerance and increased insulin sensitivity. Pharmacological blockade of central M3Rs may be a novel strategy for the treatment of obesity and associated metabolic disorders.&lt;/p&gt;&lt;p&gt;In the airway, vagally-mediated bronchoconstriction responses were abolished in M3R knockout mice in vivo, suggesting that M3R antagonists may be useful in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Studies with M3R knockout mice also have shown that the M3R is the major muscarinic receptor mediating ACh-induced glandular secretion from exocrine and endocrine glands, including the secretion of insulin from pancreatic beta cells.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:42:52 -0400</pubDate></item><item><guid isPermaLink="false">{8DF0DFB8-4632-4E05-8065-03E2F9056DFB}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/hiv-protease-gene-expression</link><title>HIV protease gene &amp; method for its expression (U.S. Patent Number 5,637,488)</title><description>&lt;p&gt;&lt;p&gt;The invention is a synthetic DNA sequence for encoding a specific enzyme or protease. The protease is essential for the completion (replication) of an infective human immunodeficiency virus (HIV). The invented gene is desirable for the expression of the protease by recombinant methodology in prokaryotic and/or eukaryotic cells and the production of a commercially desirable amount of the protease for biochemical and physical characterization, necessary to find effective inhibitor of the protease, and thereby to block the production of infectious human immunodeficiency virus (HIVs).&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:41:40 -0400</pubDate></item><item><guid isPermaLink="false">{FFF758B6-052E-476B-80EA-C8B54CBECC39}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/dihydropyridine-pyridine-benzopyran-triazoloquinazoline</link><title>Dihydropyridine-, pyridine-, Benzopyran-4-one- &amp; Triazoloquinazoline Derivative, Their Preparation, &amp; Their Use as Adenosine Receptor Antagonists (U.S. Patent Number 6,066,642)</title><description>&lt;p&gt;&lt;p&gt;The present invention provides a method of identifying CFTR-binding compounds for treating cells having a reduced apical Cl.sup.- conductance, such as cystic fibrosis cells. This identification method involves the use of polypeptide I.alpha., which constitutes a portion of the CFTR protein. The present invention also provides a method of treating CF cells by contacting cells having a reduced apical Cl.sup.- conductance with a therapeutically effective quantity of a compound selected by the present inventive identification method. Preferred compounds for such treatment have little or no affinity for adenosine cell receptors. The present invention provides novel compounds useful in practicing the present inventive method, as well as pharmaceutical compositions containing such compounds. &lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:41:12 -0400</pubDate></item><item><guid isPermaLink="false">{12090E46-B44A-4345-9993-4B35396A2F9C}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/detection-treatment-polycystic-kidney-disease</link><title>Detection &amp; treatment of polycystic kidney disease (U.S. Patent Number 7,553,644)</title><description>&lt;p&gt;Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:40:22 -0400</pubDate></item><item><guid isPermaLink="false">{522B3801-96F0-4AEA-93A6-76D8FC71CE5A}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/dendrimer-conjugates-agonists-antagonists-gprc</link><title>Dendrimer Conjugates of Agonists &amp; Antagonists of the GPCR Superfamily (U.S. Patent Number 8,153,781)</title><description>&lt;p&gt;&lt;p&gt;Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A1 adenosine receptor agonist having a purine nucleoside moiety and a functional group at the N6 position of the purine nucleoside moiety, wherein the functional group has the formula (I):&lt;br /&gt;N6H-Ar1-CH2-C(??�O)NH-R1 (I), wherein Ar1 and R1 as defined herein. Also disclosed are pharmaceutical compositions, methods of treating various diseases, and a diagnostic method employing such conjugates.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:39:35 -0400</pubDate></item><item><guid isPermaLink="false">{14338D65-D0A1-4700-953F-D5F085B636C0}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/compositions-methods-vaccine-virus-production</link><title>Compositions &amp; methods for vaccine &amp; virus production (U.S. Patent Application Number WO 2009126308 A2)</title><description>&lt;p&gt;&lt;p&gt;The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdkl3, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:39:13 -0400</pubDate></item><item><guid isPermaLink="false">{129DE471-F4D4-4F2D-AFE2-87AB9E69408C}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/compositions-methods-inhibiting-nf-kappa-beta-sod-1</link><title>Compositions &amp; methods for inhibiting NF-κB &amp; SOD-1 to treat amyotrophic lateral sclerosis (U.S. Patent Number 9,725,719)</title><description>&lt;p&gt;The invention relates to the pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to the pharmaceutical compositions, kits, methods to inhibit NF-κB in microglia or macrophages which will delay motor neuron death.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:38:47 -0400</pubDate></item><item><guid isPermaLink="false">{19FBC260-4CD2-4950-A061-9C7F8E98DEA2}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/cells-expressing-apolipoprotein-e-uses-thereof</link><title>Cells expressing Apolipoprotein E &amp; uses thereof (U.S. Patent Number PCT/US2015/049674)</title><description>&lt;p&gt;This patent covers cellular models expressing variants of the human gene Apolipoprotein E. This invention not only allows for the evaluation of cellular phenotypes but also enables the creation of models for genetic and chemical screening.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:38:28 -0400</pubDate></item><item><guid isPermaLink="false">{3C135B93-8ADC-4CE4-A3CC-C5EDDB9E8B97}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/body-weight-simulator-java-applet</link><title>Body Weight Simulator - Java Applet for Modeling Human Metabolism &amp; Energy Expenditure for Adaptive Dieting &amp; Exercise Regimens</title><description>&lt;p&gt;&lt;p&gt;Known methods for predicting weight loss fail to account for slowing of metabolism as weight is lost and therefore overestimate the degree of weight loss. While this limitation of the 3500 Calorie per pound rule has been known for some time, it was not clear how to dynamically account for the metabolic slowing. The invention provides a Java applet for modeling of human metabolism to improve the weight change predictions. The model has been validated using previously published human data and the model equations have been published. A web-based implementation of the published dynamic model has been created to allow users to perform simulations for planning weight loss interventions in adults and accounts for individual differences in metabolism and body composition. Values to the user include being able to see whether the target weight loss is realistic when the necessary caloric restriction, exercise and timeframe components are highlighted. Unrealistic goals become apparent. More moderate goals may result in greater long term success. The model also defines the caloric intake to be followed once the new weight target has been met to prevent weight being regained.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:37:28 -0400</pubDate></item><item><guid isPermaLink="false">{D71605A7-477D-4691-B0C7-7652E866931D}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/anthrose-based-compositions-related-methods</link><title>Anthrose Based Compositions &amp; Related Methods US 2015/0265691</title><description>&lt;p&gt;This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier.&lt;/p&gt;</description><pubDate>Thu, 14 Sep 2023 10:27:29 -0400</pubDate></item><item><guid isPermaLink="false">{852563CD-949C-4C86-8E88-F29045B1DC95}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/adenosine-receptor-agonists</link><title>Adenosine receptor agonists, partial agonists, &amp; antagonists (U.S. Patent Number 13/479,973)</title><description>&lt;p&gt;&lt;p&gt;NIDDK announces the availability of a highly selective A1 adenosine receptor (AR) agonist. This receptor is neuroprotective in ischemic and epileptic models. The A1AR-selective full agonist MRS5474 displayed anticonvulsant activity in vivo in a model of minimal clonic seizures, without toxicity characteristic of other A1AR agonists. Nucleoside docking to a homology model based on recently reported agonist-bound AR structures characterized the interaction of cycloalkylrelated constituents with a small hydrophobic subpocket in the A1AR. Recent advances in specificity to the A1AR encourage development of these agonists for CNS disorders. Work on the structure activity relationship of candidate molecules and the human A1AR revealed that substituents larger than cyclobutyl greatly reduced the AR affinity, and groups that were much larger or smaller than cyclopropyl abolished A1AR selectivity. The group of truncated derivatives that were developed have more drug-like physical properties than other A1AR agonists; this approach is appealing for preclinical development. &lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 13 Sep 2023 16:45:58 -0400</pubDate></item><item><guid isPermaLink="false">{0A12B8A1-5DE4-4EFB-A381-58AFCCB921AA}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/a3-adenosine-receptor-partial-agonists</link><title>A3 Adenosine Receptor Antagonists &amp; Partial Agonists (U.S. Patent Application Number 13/056,997)</title><description>&lt;p&gt;&lt;p&gt;Disclosed are A3 adenosine receptor antagonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The antagonists or partial agonists find use in treating a number of diseases including cancer, glaucoma, inflammatory diseases, asthma, stroke, myocardial infarction, allergic reactions, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, brain arteriole diameter constriction, bronchoconstriction, and myocardial ischemia, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 13 Sep 2023 16:41:50 -0400</pubDate></item><item><guid isPermaLink="false">{1FCD9CF4-AF48-41E0-B328-9987E0F4F84E}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/triazole-derivatives-47-disubstituted-2-naphthoic-acid-receptor-antagonist</link><title>Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists</title><description>&lt;p&gt;Disclosed are novel small molecules that serve as potent and selective antagonist ligands of the P2Y&lt;sub&gt;14&lt;/sub&gt; receptor for UDP-glucose, which is a G protein-coupled receptor (GPCR). Blocking this receptor has been shown to be useful in models of asthma, diabetes, acute kidney injury and other conditions.&lt;/p&gt;</description><pubDate>Fri, 08 Sep 2023 13:45:14 -0400</pubDate></item><item><guid isPermaLink="false">{0BCED02A-03C6-4323-8267-31269FD48B72}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/novel-fixative-improved-biomolecule-quality-paraffin-embedded-tissue</link><title>Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue (U.S. Patent Number 15/774,480)</title><description>&lt;p&gt;Tissues samples collected during medical procedures, such as biopsies, are used to diagnose a wide variety of diseases. Before diagnosis, patient samples are typically processed by fixation and paraffin embedding. This fixation/embedding process is used to preserve tissue morphology and histology for subsequent evaluation. Unfortunately, most fixative agents can damage or destroy nucleic acids (RNA and DNA) and damage proteins during the fixation process, thereby potentially impairing diagnostic assessment of tissue.&lt;/p&gt;&lt;p&gt;Researchers in the National Institutes of Health (NIH) have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing.&lt;/p&gt;&lt;h2&gt;Publication&lt;/h2&gt;&lt;dl class="publications accented"&gt;            &lt;dt&gt;A Buffered Alcohol-Based Fixative for Histomorphologic and Molecular Applications.&lt;/dt&gt;            &lt;dd&gt;Perry C, Chung JY, Ylaya K, Choi CH, Simpson A, Matsumoto KT, Smith WA, Hewitt SM.&lt;/dd&gt;            &lt;dd&gt;&lt;em&gt;J Histochem Cytochem&lt;/em&gt; (2016 Jul) 64(7):425-40. &lt;a href="https://pubmed.ncbi.nlm.nih.gov/27221702/"&gt;Abstract/Full Text&lt;/a&gt;&lt;/dd&gt;&lt;/dl&gt;</description><pubDate>Wed, 23 Aug 2023 13:45:47 -0400</pubDate></item><item><guid isPermaLink="false">{02D460C3-0B61-4113-8549-F58E93D69688}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/peptide-agonists-negative-antagonists-g-protein-coupled-receptor</link><title>Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor (U.S. Patent Number 6,403,305)</title><description>&lt;p&gt;The present invention is directed to a strategy to discover small peptides that will activate any G protein coupled receptor (GPCR) or inactivate any constitutively active GPCR. The strategy uses combinatorial peptide libraries to screen millions of random peptides for agonist/negative antagonist activity. The method of the subject invention comprises expressing a peptide of a peptide library tethered to a G protein coupled receptor of interest in a cell, and monitoring the cell to determine whether the peptide is an agonist or negative antagonist of the GPCR of interest. The peptide is tethered to the GPCR by replacing the amino terminus of the GPCR with the amino terminus of a self-activating receptor, and replacing the natural peptide ligand present in the amino terminus of the self-activating receptor with the peptide of the peptide library. In one embodiment for discovery of agonists, a ligand of the self-activating receptor is used to cleave the resulting amino terminus to expose the peptide of the peptide library. In another embodiment for discovery of agonists or negative antagonists, the GPCR construct ends at the peptide so the peptide is always exposed. Preferably, the self-activating receptor is the thrombin receptor and the ligand of the self-activating receptor is thrombin.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 15:19:15 -0400</pubDate></item><item><guid isPermaLink="false">{63BC2936-35C8-4309-A810-51CE56D08B9D}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/negative-antagonists-g-protein-coupled-receptors</link><title>Methods of identifying negative antagonists for G protein coupled receptors (U.S. Patent Number 6,087,115)</title><description>&lt;p&gt;The present invention is directed to a constitutively active G protein coupled receptor of human herpesvirus 8, as well as a method of identifying negative antagonists of a constitutively active G protein coupled receptor. The method comprises co-expressing in a host cell a constitutively active G protein coupled receptor and a reporter protein, wherein expression of the reporter protein is controlled by a promoter responsive to a signalling pathway activated by the constitutively active G protein coupled receptor; exposing the host cell to a test substance; and determining a level of reporter protein activity, wherein the level of reporter protein activity indicates effectiveness of the test substance as a negative antagonist of the constitutively active G protein coupled receptor. The invention further provides a method of preventing tumor formation or cell proliferation caused by a constitutively active G protein coupled receptor. This method comprises administering an amount of the negative antagonist so identified to a subject in an amount effective to prevent tumor formation or cell proliferation.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 15:14:43 -0400</pubDate></item><item><guid isPermaLink="false">{E29E9E7E-8906-4B16-A3CB-14EC5BF6FD98}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/bacillus-anthracis-protective-antigen-vaccines</link><title>Methods for preparing Bacillus anthracis protective antigen for use in vaccines (U.S. Patent Number 7,763,451)</title><description>&lt;p&gt;&lt;p&gt;The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 15:08:04 -0400</pubDate></item><item><guid isPermaLink="false">{63C64090-EC5B-4223-8922-F4B394C0E8F4}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/regulate-cell-signaling-chemokines</link><title>Receptors that regulate cell signaling relating to chemokines (U.S. Patent Number 6,365,356)</title><description>&lt;p&gt;A method for discovering molecules that regulate cell signaling specific to the dual presence of Duffy antigen receptor for chemokines (DARC) and a chemokine receptor selected from the group consisting of a CXC receptor, a CC receptor and a CXXXC receptor, the method comprising providing a cell that co-expresses DARC and the chemokine receptor; incubating the molecules with the cell; measuring the cell signaling in the cell specific to the dual presence of DARC and the chemokine receptor; and determining whether the cell signaling specific to the dual presence of DARC and the chemokine receptor is regulated by the molecules.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 15:00:13 -0400</pubDate></item><item><guid isPermaLink="false">{F5D1FB49-A8B3-428F-B980-6BF18AC1335C}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/preventing-viral-replication</link><title>Methods of preventing viral replication (U.S. Patent Number 5,610,050)</title><description>&lt;p&gt;&lt;p&gt;The invention relates to methods and compositions for inhibition of viral replication. In particular, termination of replication of hepatitis B virus is achieved by introducing into a target cell an antisense oligonucleotide having a sequence substantially complementary to an mRNA which is in turn complementary to a portion of the minus strand of a hepatitis viral genome, which portion encoding solely part or all of the terminal protein region of the viral polymerase.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 14:52:40 -0400</pubDate></item><item><guid isPermaLink="false">{37C2F864-1528-4D7A-A189-FE0F5D61A2A7}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/pituitary-trh-receptor</link><title>Pituitary TRH receptor (U.S. Patent Number 5,288,621)</title><description>&lt;p&gt;&lt;p&gt;Disclosed for the first time is the isolation, sequence, and expression cloning of a cDNA encoding for pituitary thyrotropin-releasing hormone receptor, as well as the amino acid sequence for the receptor per se.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 14:23:04 -0400</pubDate></item><item><guid isPermaLink="false">{ABBC8AD5-1B08-4501-9D45-82688D4EFE9B}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/hgc-1-gene-olfactomedin-protein</link><title>hGC-1, a gene encoding a member of the olfactomedin-related protein family (U.S. Patent Number 7,557,196)</title><description>&lt;p&gt;&lt;p&gt;An isolated acid having the sequence of a) SEQ ID NO: 1; b) the sequence of SEQ ID NO: 2; c) the sequence of SEQ ID NO: 3; d) a sequence complementary to any of a), b), or c); or e) a sequence of at least 10 contiguous nucleotides specific for any of a)-d). The invention relates to the identification and characterization of a hitherto unidentified human gene, hGC-1. The protein encoded by hGC-1 appears to be a member of the olfactomedin-related proteins. The invention relates generally to the gene (hGC-1), nucleic acids, cDNA, vectors, polypeptides, protein, antibodies, cells, transgenic animal, and other compositions related to hGC-1. Additionally, primers are provided for identifying hGC-1. The invention further relates to methods of using these compositions, such as diagnosis and treatment of various cancers, and kits comprising these compositions.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 14:11:22 -0400</pubDate></item><item><guid isPermaLink="false">{AA12D4DC-2340-4626-937D-53380C04708E}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/a3-adenosine-receptor-antagonists</link><title>A3 Adenosine Receptor Antagonists (U.S. Patent Number 6,376,521)</title><description>&lt;p&gt;&lt;p&gt;This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. &lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 14:03:10 -0400</pubDate></item><item><guid isPermaLink="false">{AB1C6162-1CA3-4280-89B2-6F1DC246624D}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/transframe-peptide-inhibitor-viral-protease</link><title>Transframe peptide inhibitor of viral protease (U.S. Patent Number 5,872,210)</title><description>&lt;p&gt;&lt;p&gt;The present invention describes small, water soluble peptides isolated from a native virus inhibitory sequence that blocks maturation of the virally encoded protease and inhibits the mature protease as well. The peptides may be used in the treatment of virally infected cells, in the preparation of vaccine formulations, in the generation of clinically relevant antibodies and anti-idiotypic antibodies and in the generation of a screening assay or kit that can be used to identify other similarly acting protease inhibitors. &lt;br /&gt;&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 11:21:42 -0400</pubDate></item><item><guid isPermaLink="false">{9EAF4D51-9104-41CD-95E2-047CB90975E0}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/single-electrode-corona-discharge-electrochemical-electrospray-ionization</link><title>Single electrode corona discharge electrochemical/electrospray ionization (U.S. Patent Number 7,759,643)</title><description>&lt;p&gt;A single electrode electrochemical/electrospray ionization source using a corona discharge and a method of analyzing a sample using a corona discharge single electrode electrochemical/electrospray ionization source are provided. In the corona discharge single electrode electrochemical/electrospray ionization technique electrons are removed from the metal tip of the device through gases present in the electrospray ion source resulting in electrochemical ionization of the sample of interest. The resulting odd electron sample cation (positive ion mode) or anion (negative ion mode) can then be analyzed by an appropriate technique, such as, for example, a mass spectrometer.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 11:05:38 -0400</pubDate></item><item><guid isPermaLink="false">{6895BA41-63EA-4B9B-B52C-D98AA67970C8}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/carbohydrates-amine-containing-carriers</link><title>Linking compounds useful for coupling carbohydrates to amine-containing carriers (U.S. Patent Number 5,952,454)</title><description>&lt;p&gt;&lt;p&gt;The present invention provides a method to couple a glycosyl donor to an amine-containing carrier or substrate material using as a spacer a compound of the general formula I: ##STR1## in which n and m are each independently an integer of from 1 to 12, R.sub.1 and R.sub.2 are each independently H, lower alkyl, a hydroxyl group, or a substituent which does not interfere with the linking reactions, R.sub.4 and R.sub.5 are each independently H, lower alkyl, a hydroxyl group, or a substituent which does not interfere with the linking reactions, R.sub.3 and R'.sub.3 are each independently an optionally substituted lower alkyl or R.sub.3 and R'.sub.3 can be joined to form an optionally substituted cyclic moiety having from 2 to 5 carbon atoms.&lt;/p&gt;&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 10:54:20 -0400</pubDate></item><item><guid isPermaLink="false">{C791585E-3B3C-400C-82C0-58453A10B550}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/over-expression-rapid-purification-biosynthetic-proteins</link><title>Method for over-expression of rapid purification of biosynthetic proteins (U.S. Patent Number 6,077,694)</title><description>&lt;p&gt;The subject invention relates to a method of producing and purifying large quantities of a biosynthetic protein. The gene which codes for the protease is placed between the binding domain of a gene which codes for a binding protein and a gene coding for the target protein of interest. The fused gene construct is inserted in an expression vector which is then introduced into a host cell.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 10:42:14 -0400</pubDate></item><item><guid isPermaLink="false">{62BC3C70-2C31-4F86-9997-51640237BC80}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/polycystic-kidney-disease-gene-us-patent</link><title>Polycystic kidney disease gene (U.S. Patent Number 5,654,170)</title><description>&lt;p&gt;The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells transformed with the vectors, and methods for producing PKD1 protein or fragments thereof. In another aspect, the invention involves isolated oligonucleotides that hybridize only to the authentic expressed PKD1 gene, and not to PKD1 homologues. In yet another aspect, the invention involves isolated mutant PKD1 genes, and their cDNA cognates. Further provided are isolated oligonucleotides that discriminate between normal and mutant versions of the PKD1 gene. Methods and compositions for treating APKD or disease conditions having the characteristics of APKD are also provided.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 10:31:30 -0400</pubDate></item><item><guid isPermaLink="false">{48E83397-E881-4390-B2E7-19B2D1555710}</guid><link>https://www.niddk.nih.gov/research-funding/technology-advancement-transfer/research-materials-licensing/polycystic-kidney-disease-gene-patent</link><title>Polycystic kidney disease gene (Patent Number 6,867,288)</title><description>&lt;p&gt;The present invention provides methods and compositions for treating cyst formation in PKD1-associated epithelial cells. Such methods encompass administering an isolated human PKD1 gene, or fragments of the gene, under conditions that result in expression of therapeutically effective amounts of all, or part of, the PKD1 protein. The invention also encompasses compositions for treating cyst formation associated with APKD.&lt;/p&gt;</description><pubDate>Wed, 05 Apr 2023 10:21:37 -0400</pubDate></item></channel></rss>